Royal Bank of Canada decreased its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 6.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,106 shares of the biopharmaceutical company’s stock after selling 909 shares during the period. Royal Bank of Canada’s holdings in Cytokinetics were worth $159,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the business. Parametric Portfolio Associates LLC increased its stake in Cytokinetics by 1.4% in the 1st quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 189 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Cytokinetics by 0.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 84,509 shares of the biopharmaceutical company’s stock valued at $1,022,000 after buying an additional 688 shares during the last quarter. ProShare Advisors LLC increased its stake in Cytokinetics by 7.5% in the 2nd quarter. ProShare Advisors LLC now owns 27,501 shares of the biopharmaceutical company’s stock valued at $333,000 after buying an additional 1,926 shares during the last quarter. UBS Group AG increased its stake in Cytokinetics by 16.9% in the 1st quarter. UBS Group AG now owns 14,281 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 2,060 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Cytokinetics by 36.8% during the 1st quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 3,383 shares during the last quarter. Hedge funds and other institutional investors own 71.92% of the company’s stock.

In other news, insider Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $12.94, for a total transaction of $55,124.40. Following the completion of the sale, the insider now directly owns 17,982 shares of the company’s stock, valued at approximately $232,687.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Santo J. Costa sold 5,000 shares of Cytokinetics stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $14.00, for a total transaction of $70,000.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $70,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 178,223 shares of company stock valued at $2,639,239. Insiders own 7.20% of the company’s stock.

Cytokinetics, Incorporated (CYTK) opened at $7.60 on Friday. Cytokinetics, Incorporated has a fifty-two week low of $7.00 and a fifty-two week high of $17.20. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%. The firm had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. equities analysts expect that Cytokinetics, Incorporated will post -2.4 EPS for the current fiscal year.

Several brokerages have recently issued reports on CYTK. Zacks Investment Research lowered shares of Cytokinetics from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Cantor Fitzgerald restated a “buy” rating and set a $21.00 price target on shares of Cytokinetics in a research note on Monday, September 18th. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Cytokinetics in a research note on Wednesday, September 20th. TheStreet lowered shares of Cytokinetics from a “c” rating to a “d” rating in a research note on Friday, October 27th. Finally, Needham & Company LLC lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and decreased their price target for the stock from $22.00 to $12.00 in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.64.

TRADEMARK VIOLATION NOTICE: “Royal Bank of Canada Has $159,000 Holdings in Cytokinetics, Incorporated (CYTK)” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/royal-bank-of-canada-has-159000-holdings-in-cytokinetics-incorporated-cytk/1726853.html.

About Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.